Literature DB >> 8804434

Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.

H Sato1, T Kinoshita, T Takino, K Nakayama, M Seiki.   

Abstract

Membrane type 1-matrix metalloproteinase (MT1-MMP) initiates the activation of the zymogen progelatinase A/ 72-kDa type IV collagenase by cleavage of the Asn66-Leu peptide bond. We previously pointed out that MT1-MMP possesses a unique amino acid sequence Arg-Arg-Lys-Arg111 which is a potential recognition sequence for furin-like proteases (Nature, 370 (1994) 61-65). Here, using a recombinant MT1-MMP expressed in Escherichia coli we demonstrated that furin specifically cleaves MT1-MMP between Arg111-Tyr in vitro, which resulted in a stimulation of progelatinase A-activation function. Tissue inhibitor of metalloproteinases (TIMP)-2 inhibited activation of progelatinase A by forming a stable complex with activated MT1-MMP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804434     DOI: 10.1016/0014-5793(96)00861-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  70 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 3.  Matrix remodeling during endochondral ossification.

Authors:  Nathalie Ortega; Danielle J Behonick; Zena Werb
Journal:  Trends Cell Biol       Date:  2004-02       Impact factor: 20.808

Review 4.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

5.  NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.

Authors:  Sarah L McLaughlin; Ryan J Ice; Anuradha Rajulapati; Polina Y Kozyulina; Ryan H Livengood; Varvara K Kozyreva; Yuriy V Loskutov; Mark V Culp; Scott A Weed; Alexey V Ivanov; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2013-11-07       Impact factor: 5.852

Review 6.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

7.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

8.  The cytoplasmic tail dileucine motif LL572 determines the glycosylation pattern of membrane-type 1 matrix metalloproteinase.

Authors:  Thomas Ludwig; Sarah M Theissen; Michael J Morton; Michael J Caplan
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

9.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury.

Authors:  Soo Young Park; Hye Won Shin; Kyoung Bun Lee; Min-Jae Lee; Ja-June Jang
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.